Clinical Trial Update: Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults [Phase 2]

View source ↗

Summary

Phase 2 trial updates on shedding, immunogenicity, and safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected children and young adult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Quadrivalent live intranasal influenza vaccine (QLAIV) (Quadrivalent live attenuated influenza vaccine)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Human Immunodeficiency Virus (HIV) | Phase 2 | Status: COMPLETED | Results posted: 2017-10-16